Romain BUISSON/LinkedIn
Nov 5, 2025, 05:14
Penumbra Announces Secondary Results of the Ground-Breaking STORM – PE RCT
Romain Buisson, Country Manager (TH-HK cluster) at Penumbra, Inc., shared a post by Penumbra, Inc. on LinkedIn:
”Latest updates in STORM PE
Patient treated with CAVT plus anticoagulation experienced significantly longer distance walked during the 90-day six-minute walk test (472m vs 376m; P = 0.019).
CAVT patients near normalized by 90 days, walking 94% of their predicted walk distance vs 75% in the anticoagulation only arm (P = 0.022)”
Quoting Penumbra, Inc.’s post:
”Penumbra announces secondary results of the ground-breaking STORM-PE RCT at VIVA 2025. Read more here.”
Stay updated with Hemostasis Today.
-
Apr 16, 2026, 16:10Hamid Noori: Etiological Classification of Anemia Understanding the Root Cause
-
Apr 16, 2026, 15:29Sebastian Klapa: Key Findings On Mortality And Cardiovascular Risk In ANCA-Associated Vasculitis
-
Apr 16, 2026, 15:23Ifeanyichukwu Ifechidere: Argatroban – Its ‘Rescue Mission’ in Heparin-Induced Thrombocytopenia
-
Apr 16, 2026, 14:58Early Diagnosis Can Change Everything in Hemophilia Care – WFH
-
Apr 16, 2026, 14:05Saleh Shamse Basha: When Platelet Counts Mislead, The PLT-F Becomes Critical
-
Apr 16, 2026, 13:44Maha Othman: Celebrating National Medical Laboratory Week in Canada
-
Apr 16, 2026, 13:42Megan Adediran: How Much of What You Know About Hemophilia Is True?
-
Apr 16, 2026, 13:35Priya Singh: How to Write the Discussion of a Research Paper
-
Apr 16, 2026, 13:14Veronica Sanchez: Blood Pressure Categories for Individuals Who Are Pregnant